Silencing of miR-370 in Human Cholangiocarcinoma by Allelic Loss and Interleukin-6 Induced Maternal to Paternal Epigenotype Switch

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  An, Fangmei ^a,b,c   Yamanaka, Sumitaka ^a   Allen, Sarah ^d   Roberts, Lewis R ^e   Gores, Gregory J ^e   Pawlik, Timothy M ^a   Xie, Qing ^b   Ishida, Masaharu ^a   Mezey, Esteban ^a   Ferguson Smith, Anne C ^d   Mori, Yuriko ^a   Selaru, Florin M ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c WUXI PEOPLE S HOSPITAL AFFILIATED TO NANJING MEDICAL UNIVERSITY   (China)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6; MICRORNA; MIR 370; UNCLASSIFIED DRUG; WNT10B PROTEIN;

ALLELE; ANIMAL TISSUE; ARTICLE; BILE DUCT CARCINOMA; COHORT ANALYSIS; CONTROLLED STUDY; DEMETHYLATION; DNA METHYLATION; DNA STRUCTURE; EMBRYO; GENE EXPRESSION; GENE LOSS; GENE SILENCING; GENE SWITCHING; GENOME IMPRINTING; HUMAN; HUMAN CELL; HUMAN TISSUE; INTERGENIC DIFFERENTIALLY METHYLATED REGION; MATERNAL ALLELE; MOUSE; NONHUMAN; PATERNAL ALLELE; REGULATORY MECHANISM; UPREGULATION;

ANIMALS; BLOTTING, WESTERN; CELL LINE, TUMOR; CHOLANGIOCARCINOMA; DNA METHYLATION; HUMANS; INTERLEUKIN-6; LOSS OF HETEROZYGOSITY; MICE; MICRORNAS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84867707606     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0045606     Document Type: Article

References (45)

1. Blechacz B, Gores GJ, (2008) Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology 48: 308-321.
2. Zografos GN, Farfaras A, Zagouri F, Chrysikos D, Karaliotas K, (2011) Cholangiocarcinoma: principles and current trends. Hepatobiliary Pancreat Dis Int 10: 10-20.
3. Meng F, Yamagiwa Y, Ueno Y, Patel T, (2006) Over-expression of interleukin-6 enhances cell survival and transformed cell growth in human malignant cholangiocytes. J Hepatol 44: 1055-1065.
4. Boumber Y, Issa JP, (2011) Epigenetics in cancer: what's the future? Oncology (Williston Park) 25: 220-226, 228.
5. Isomoto H, (2009) Epigenetic alterations associated with cholangiocarcinoma (review). Oncol Rep 22: 227-232.
6. Tischoff I, Wittekind C, Tannapfel A, (2006) Role of epigenetic alterations in cholangiocarcinoma. J Hepatobiliary Pancreat Surg 13: 274-279.
7. Lee S, Kim WH, Jung HY, Yang MH, Kang GH, (2002) Aberrant CpG island methylation of multiple genes in intrahepatic cholangiocarcinoma. Am J Pathol 161: 1015-1022.
8. Wehbe H, Henson R, Meng F, Mize-Berge J, Patel T, (2006) Interleukin-6 contributes to growth in cholangiocarcinoma cells by aberrant promoter methylation and gene expression. Cancer Res 66: 10517-10524.
9. Ferguson-Smith AC, (2011) Genomic imprinting: the emergence of an epigenetic paradigm. Nat Rev Genet 12: 565-575.
10. Barlow DP, (2011) Genomic Imprinting: A Mammalian Epigenetic Discovery Model. Annu Rev Genet.
11. Crouse HV, (1960) The Controlling Element in Sex Chromosome Behavior in Sciara. Genetics 45: 1429-1443.
12. Barlow DP, Stoger R, Herrmann BG, Saito K, Schweifer N, (1991) The mouse insulin-like growth factor type-2 receptor is imprinted and closely linked to the Tme locus. Nature 349: 84-87.
13. Ferguson-Smith AC, Cattanach BM, Barton SC, Beechey CV, Surani MA, (1991) Embryological and molecular investigations of parental imprinting on mouse chromosome 7. Nature 351: 667-670.
14. Bartolomei MS, Zemel S, Tilghman SM, (1991) Parental imprinting of the mouse H19 gene. Nature 351: 153-155.
15. Rainier S, Johnson LA, Dobry CJ, Ping AJ, Grundy PE, et al. (1993) Relaxation of imprinted genes in human cancer. Nature 362: 747-749.
16. Ogawa O, Eccles MR, Szeto J, McNoe LA, Yun K, et al. (1993) Relaxation of insulin-like growth factor II gene imprinting implicated in Wilms' tumour. Nature 362: 749-751.
17. Brown KW, Villar AJ, Bickmore W, Clayton-Smith J, Catchpoole D, et al. (1996) Imprinting mutation in the Beckwith-Wiedemann syndrome leads to biallelic IGF2 expression through an H19-independent pathway. Hum Mol Genet 5: 2027-2032.
18. Suzuki H, Ueda R, Takahashi T, (1994) Altered imprinting in lung cancer. Nat Genet 6: 332-333.
19. Randhawa GS, Cui H, Barletta JA, Strichman-Almashanu LZ, Talpaz M, et al. (1998) Loss of imprinting in disease progression in chronic myelogenous leukemia. Blood 91: 3144-3147.
20. Schwienbacher C, Gramantieri L, Scelfo R, Veronese A, Calin GA, et al. (2000) Gain of imprinting at chromosome 11p15: A pathogenetic mechanism identified in human hepatocarcinomas. Proc Natl Acad Sci U S A 97: 5445-5449.
21. Harris TM, Rogler LE, Rogler CE, (1998) Reactivation of the maternally imprinted IGF2 allele in TGFalpha induced hepatocellular carcinomas in mice. Oncogene 16: 203-209.
22. Edwards CA, Mungall AJ, Matthews L, Ryder E, Gray DJ, et al. (2008) The evolution of the DLK1-DIO3 imprinted domain in mammals. PLoS Biol 6: e135.
23. Olaru AV, Ghiaur G, Yamanaka S, Luvsanjav D, An F, et al. (2011) A microRNA downregulated in human cholangiocarcinoma controls cell cycle through multiple targets involved in the G1/S checkpoint. Hepatology.
24. Meng F, Wehbe-Janek H, Henson R, Smith H, Patel T, (2008) Epigenetic regulation of microRNA-370 by interleukin-6 in malignant human cholangiocytes. Oncogene 27: 378-386.
25. Georgiades P, Watkins M, Surani MA, Ferguson-Smith AC, (2000) Parental origin-specific developmental defects in mice with uniparental disomy for chromosome 12. Development 127: 4719-4728.
26. Lin SP, Youngson N, Takada S, Seitz H, Reik W, et al. (2003) Asymmetric regulation of imprinting on the maternal and paternal chromosomes at the Dlk1-Gtl2 imprinted cluster on mouse chromosome 12. Nat Genet 35: 97-102.
27. Kagami M, O'Sullivan MJ, Green AJ, Watabe Y, Arisaka O, et al. (2010) The IG-DMR and the MEG3-DMR at human chromosome 14q32.2: hierarchical interaction and distinct functional properties as imprinting control centers. PLoS Genet 6: e1000992.
28. Kagami M, Sekita Y, Nishimura G, Irie M, Kato F, et al. (2008) Deletions and epimutations affecting the human 14q32.2 imprinted region in individuals with paternal and maternal upd(14)-like phenotypes. Nat Genet 40: 237-242.
29. Razumilava N, Bronk SF, Smoots RL, Fingas CD, Werneburg NW, et al. miR-25 targets TRAIL death Receptor-4 and promotes apoptosis resistance in cholangiocarcinoma. Hepatology.
30. Selaru FM, Olaru AV, Kan T, David S, Cheng Y, et al. (2009) MicroRNA-21 is overexpressed in human cholangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloproteinase 3. Hepatology 49: 1595-1601.
31. Seitz H, Royo H, Bortolin ML, Lin SP, Ferguson-Smith AC, et al. (2004) A large imprinted microRNA gene cluster at the mouse Dlk1-Gtl2 domain. Genome Res 14: 1741-1748.
32. Sirica AE, (2005) Cholangiocarcinoma: molecular targeting strategies for chemoprevention and therapy. Hepatology 41: 5-15.
33. Kang YK, Kim YI, Kim WH, (2000) Allelotype analysis of intrahepatic cholangiocarcinoma. Mod Pathol 13: 627-631.
34. Cazals-Hatem D, Rebouissou S, Bioulac-Sage P, Bluteau O, Blanche H, et al. (2004) Clinical and molecular analysis of combined hepatocellular-cholangiocarcinomas. J Hepatol 41: 292-298.
35. Lane TF, Leder P, (1997) Wnt-10b directs hypermorphic development and transformation in mammary glands of male and female mice. Oncogene 15: 2133-2144.
36. Steg A, Wang W, Blanquicett C, Grunda JM, Eltoum IA, et al. (2006) Multiple gene expression analyses in paraffin-embedded tissues by TaqMan low-density array: Application to hedgehog and Wnt pathway analysis in ovarian endometrioid adenocarcinoma. J Mol Diagn 8: 76-83.
37. Khan NI, Bradstock KF, Bendall LJ, (2007) Activation of Wnt/beta-catenin pathway mediates growth and survival in B-cell progenitor acute lymphoblastic leukaemia. Br J Haematol 138: 338-348.
38. Liu X, Mazanek P, Dam V, Wang Q, Zhao H, et al. (2008) Deregulated Wnt/beta-catenin program in high-risk neuroblastomas without MYCN amplification. Oncogene 27: 1478-1488.
39. Yoshikawa H, Matsubara K, Zhou X, Okamura S, Kubo T, et al. (2007) WNT10B functional dualism: beta-catenin/Tcf-dependent growth promotion or independent suppression with deregulated expression in cancer. Mol Biol Cell 18: 4292-4303.
40. Zweers SJ, Booij KA, Komuta M, Roskams T, Gouma DJ, et al. (2012) The human gallbladder secretes fibroblast growth factor 19 (FGF19) into bile: Towards defining the role of FGF19 in the enterobiliary tract. Hepatology.
41. Tsuneyama K, Saito K, Ruebner BH, Konishi I, Nakanuma Y, et al. (2000) Immunological similarities between primary sclerosing cholangitis and chronic sclerosing sialadenitis: report of the overlapping of these two autoimmune diseases. Dig Dis Sci 45: 366-372.
42. Mori Y, Yin J, Sato F, Sterian A, Simms LA, et al. (2004) Identification of genes uniquely involved in frequent microsatellite instability colon carcinogenesis by expression profiling combined with epigenetic scanning. Cancer Res 64: 2434-2438.
43. Zou TT, Selaru FM, Xu Y, Shustova V, Yin J, et al. (2002) Application of cDNA microarrays to generate a molecular taxonomy capable of distinguishing between colon cancer and normal colon. Oncogene 21: 4855-4862.
44. Mori Y, Cai K, Cheng Y, Wang S, Paun B, et al. (2006) A genome-wide search identifies epigenetic silencing of somatostatin, tachykinin-1, and 5 other genes in colon cancer. Gastroenterology 131: 797-808.
45. Cummins JM, He Y, Leary RJ, Pagliarini R, Diaz LA Jr, et al. (2006) The colorectal microRNAome. Proc Natl Acad Sci U S A 103: 3687-3692.